Cover Image
市場調查報告書

腦性麻痺:開發平台分析

Cerebral Palsy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200937
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
腦性麻痺:開發平台分析 Cerebral Palsy - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 46 Pages
簡介

腦性麻痺是運動、學習、視聽覺、思考等腦及神經系統功能方面的障礙,其症狀有肌肉緊張、步行異常、手腕、膝蓋拘摟、甸腳尖走路、發音障礙、視聽覺障礙疼痛等。治療方法有使用抗痙攣藥和肌肉鬆弛劑等。

本報告以全球腦性麻痺治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢、藥物簡介、主要企業及其開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

腦性麻痺概要

治療藥的開發

  • 腦性麻痺開發中產品:概要
  • 腦性麻痺開發中產品:比較分析

腦性麻痺:開發中的治療藥:各企業

腦性麻痺:開發中的治療藥:大學、研究機關

腦性麻痺:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

腦性麻痺:開發中的產品:各企業

腦性麻痺:開發中的產品:大學、研究機關

腦性麻痺:開發治療藥的企業

  • Allergan Plc
  • Cell Cure Neurosciences, Ltd.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.
  • Neuralstem, Inc.

腦性麻痺:治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • NeurArrest
  • NSI-566
  • onabotulinumtoxin A
  • 腦性麻痺幹細胞治療
  • 腦性麻痺、全身性紅斑性狼瘡幹細胞治療
    • 產品概要
    • 作用機制
    • R&D的進展

腦性麻痺:最近的開發平台趨勢

腦性麻痺:暫停中的計劃

腦性麻痺:產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8222IDB

Summary

Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2016', provides an overview of the Cerebral Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy
  • The report reviews pipeline therapeutics for Cerebral Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cerebral Palsy therapeutics and enlists all their major and minor projects
  • The report assesses Cerebral Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cerebral Palsy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cerebral Palsy Overview
  • Therapeutics Development
    • Pipeline Products for Cerebral Palsy - Overview
  • Cerebral Palsy - Therapeutics under Development by Companies
  • Cerebral Palsy - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cerebral Palsy - Products under Development by Companies
  • Cerebral Palsy - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Cell Cure Neurosciences, Ltd.
    • Cellular Biomedicine Group, Inc.
    • CHA Bio & Diostech Co., Ltd.
    • CytoDel, LLC
    • Neuralstem, Inc.
  • Cerebral Palsy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Cyto-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NeurArrest - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Palsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cerebral Palsy - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cerebral Palsy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Cerebral Palsy - Pipeline by Allergan Plc, H2 2016
  • Cerebral Palsy - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016
  • Cerebral Palsy - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Cerebral Palsy - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016
  • Cerebral Palsy - Pipeline by CytoDel, LLC, H2 2016
  • Cerebral Palsy - Pipeline by Neuralstem, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cerebral Palsy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Cerebral Palsy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top